<DOC>
	<DOCNO>NCT00231608</DOCNO>
	<brief_summary>The purpose study compare effect Topiramate placebo abdominal visceral fat accumulation 6 month evaluate safety Topiramate 12 month continue treatment male patient abdominal obesity .</brief_summary>
	<brief_title>A Study Safety Efficacy Topiramate Male Patients With Abdominal Obesity</brief_title>
	<detailed_description>Topiramate approve treatment obesity . This study 6-month randomize , double-blind placebo-controlled study , follow 6-month open-label extension study evaluate effect Topiramate abdominal visceral fat accumulation , clinical surrogate know associated complication obesity increase incidence Type 2 diabetes mellitus , hypertension , dyslipidemia , associate morbidity . Patients randomize receive either daily Topiramate placebo . Effectiveness measure multiple parameter abdominal visceral fat ( assess compute tomography ) , total subcutaneous abdominal fat , body composition , body weight , body mass index , glucose tolerance , lipid profile , blood pressure , Topiramate plasma concentration , 24 hour energy expenditure ( select patient ) . Safety evaluation ( adverse event , vital sign , 12-lead ECG , clinical laboratory test ) conduct throughout study . The study hypothesis Topiramate effective reduce abdominal visceral fat male patient well tolerate . After initial 12-week titration phase , patient receive either Topiramate ( 200mg twice daily maximum dose tolerate ) placebo mouth 6-months . Then , patient receive Topiramate ( 200mg twice daily maximum tolerate dose ) 6-months open-label phase .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Obesity , Abdominal</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>BMI &gt; = 27 = &lt; 40 waist circumference &gt; = 100 cm ( 39.4 inch ) Baseline weight must stable ( vary 4 kg ( 8.8 lb ) ) least two month prior enrollment Must sedentary ( le one session continuous moderate physical activity 30 min/week ) Must blood lipid disorder Must nonsmoker Patients endocrine disease physical cause obesity Patients significantly abnormal hepatic liver function test renal disease History schizophrenia , psychotic , major affective disorder History epilepsy History eat disorder History significant medical condition</criteria>
	<gender>Male</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Abdominal Obesity</keyword>
	<keyword>Visceral Fat</keyword>
	<keyword>Subcutaneous Fat</keyword>
	<keyword>Dislipidemia</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>